Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC

Amgen (AMGN) announced that the FDA has granted accelerated approval to tarlatamab for pre-treated advanced small cell lung cancer (ES-SCLC).Tarlatamab is a delta-like ligand 3 targeting Bispecific T-cell Engager (BiTE) therapy, approved by the name of Imdelltra to treat ES-SCLC patients whose disease has progressed on or after treatment with platinum-based chemotherapy.The approval comes a month ahead of the PDUFA date on Jun 12. With the approval, Imdelltra becomes the first DLL3-targeting BiTE therapy th ...